Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 53, Issue 8, 2012, Pages 1469-1473

  Elstrom, Rebecca L ^a   Andemariam, Biree ^a,c   Martin, Peter ^a   Ruan, Jia ^a   Shore, Tsiporah B ^b   Coleman, Morton ^a   Leonard, John P ^a   Furman, Richard R ^a  

^a Center for Lymphoma and Myeloma   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

antineoplastic combined chemotherapy; Lymphoma; proteasome; recurrence

Indexed keywords

BLEOMYCIN; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MESNA; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; FOLLOW UP; HUMAN; IMMUNOTHERAPY; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CISPLATIN; COMBINED MODALITY THERAPY; DEXAMETHASONE; DISEASE-FREE SURVIVAL; ETOPOSIDE; HUMANS; IFOSFAMIDE; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864265152     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.656629     Document Type: Article

References (30)

1. C oleman M, Leonard J, Shuster MW, et al. DICE (dexamethasone ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL). Eur J Haematol Suppl 2001;64:41-45.
2. M oskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly eff ective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplanteligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3776-3785.
3. K ewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diff use large B-cell lymphoma. Blood 2004;103:3684-3688.
4. P hilip T, Chauvin F, Armitage J, et al. Parma international protocol: pilot study of DHAP followed by involved-fi eld radiotherapy and BEAC with autologous bone marrow transplantation. Blood 1991;77: 1587-1592.
5. V elasquez WS, McLaughlin P, Tucker S, et al. ESHAP-an eff ective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169-1176.
6. G irouard C, Dufresne J, Imrie K, et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation. Ann Oncol 1997;8:675-680.
7. G isselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184-4190.
8. G ianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290-1297.
9. Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diff use aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001;19:406-413.
10. M oskowitz C. Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy. Cancer Chemother Pharmacol 2002;49(Suppl. 1):S9-S12.
11. Mitsiades N, Mitsiades CS, Richardson PG, et al. Th e proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-2380.
12. D unleavy K, Janik J, Gea-Banacloche J, et al. Phase I/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma. Blood 2004;104(Suppl. 1): Abstract 1385.
13. Dunleavy K, Pittaluga S, Czuczman MS, et al. Diff erential effi cacy of bortezomib plus chemotherapy within molecular subtypes of diff use large B-cell lymphoma. Blood 2009;113:6069-6076.
14. R uan J, Martin P, Furman RR, et al. Bortezomib plus CHOPrituximab for previously untreated diff use large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690-697.
15. Hans CP, Weisenburger DD, Greiner TC, et al. Confi rmation of the molecular classifi cation of diff use large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275-282.
16. Cheson BD, Pfi stner B, Juweid ME, et al. Revised response criteria or malignant lymphoma. J Clin Oncol 2007;25:579-586.
17. S imon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
18. Hoppe BS, Moskowitz CH, Zhang Z, et al. Th e role of FDG-PET imaging and involved fi eld radiotherapy in relapsed or refractory diff use large B-cell lymphoma. Bone Marrow Transplant 2009;43:941-948.
19. Derenzini E, Musuraca G, Fanti S, et al. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer 2008;113:2496-2503.
20. D ickinson M, Hoyt R, Roberts AW, et al. Improved survival for relapsed diff use large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy. Br J Haematol 2010;150:39-45.
21. Hideshima T, Richardson P, Chauhan D, et al. Th e proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-3076.
22. B ernal-Mizrachi L, Lovly CM, Ratner L. Th e role of NF-{kappa}B-1 and NF-{kappa}B-2-mediated resistance to apoptosis in lymphomas. Proc Natl Acad Sci USA 2006;103:9220-9225.
23. R osenwald A, Wright G, Chan WC, et al. Th e use of molecular profi ling to predict survival after chemotherapy for diff use large-B-cell lymphoma. N Engl J Med 2002;346:1937-1947.
24. M oskowitz CH, Zelenetz AD, Kewalramani T, et al. Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 2005;106:3383-3385.
25. Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001;82:110-122.
26. P erez-Galan P, Roue G, Villamor N, et al. Th e proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006;107:257-264.
27. S trauss SJ, Higginbottom K, Juliger S, et al. Th e proteasome nhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res 2007;67:2783-2790.
28. G u H, Chen X, Gao G, et al. Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells. Mol Cancer Th er 2008;7: 2298-2307.
29. Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin lymphoma. J Clin Oncol 2008;26:5165-5169.
30. Williams CD, Harrison CN, Lister TA, et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 2001;19:727-735.